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Abstract
Norepinephrine regulates latent neural stem cell activity and adult hippocampal neurogenesis, and has an important role in
modulating hippocampal functions such as learning, memory and mood. Adult hippocampal neurogenesis is a multi-stage
process, spanning from the activation and proliferation of hippocampal stem cells, to their differentiation into neurons.
However, the stage-specific effects of noradrenergic receptors in regulating adult hippocampal neurogenesis remain poorly
understood. In this study, we used transgenic Nestin-GFP mice and neurosphere assays to show that modulation of a2- and
b-adrenergic receptor activity directly affects Nestin-GFP/GFAP-positive precursor cell population albeit in an opposing
fashion. While selective stimulation of a2-adrenergic receptors decreases precursor cell activation, proliferation and
immature neuron number, stimulation of b-adrenergic receptors activates the quiescent precursor pool and enhances their
proliferation in the adult hippocampus. Furthermore, our data indicate no major role for a1-adrenergic receptors, as we did
not observe any change in either the activation and proliferation of hippocampal precursors following selective stimulation
or blockade of a1-adrenergic receptors. Taken together, our data suggest that under physiological as well as under
conditions that lead to enhanced norepinephrine release, the balance between a2- and b-adrenergic receptor activity
regulates precursor cell activity and hippocampal neurogenesis.
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Introduction
The mammalian hippocampal neurogenic niche retains quies-
cent neural precursor cells that generate newborn neurons
throughout life [1,2]. This process of adult hippocampal neuro-
genesis is a unique form of structural plasticity that has been
implicated in the regulation of hippocampus-specific cognitive and
mood-related functions [3,4]. Though we know the process is
tightly controlled and subject to regulation at various stages,
including the activation and proliferation of precursors, as well as
their differentiation, survival and integration into existing func-
tional networks [3,5,6], the detailed molecular mechanisms that
regulate of each of these stages are not yet fully elucidated.
The neurogenic niche in the adult hippocampus is densely
innervated by monoaminergic axon terminals, particularly nor-
adrenergic terminals that arise from locus coeruleus neurons in the
brain stem [7]. Numerous studies have shown norepinephrine to
have a positive effect on hippocampal neurogenesis [1,8,9] and the
modulation of neurogenesis-related functions such as learning,
memory and mood [10–13]. Our previous work has demonstrated
that pharmacological depletion of norepinephrine leads to a robust
decline in hippocampal precursor cell proliferation [8] and, more
recently, we have shown that norepinephrine directly activates a
quiescent population of hippocampal stem/precursor cells [1].
Interestingly, clinical antidepressants that block the re-uptake of
norepinephrine have also been reported to increase precursor cell
proliferation and enhance hippocampal neurogenesis [1,9].
Norepinephrine signals via a family of adrenergic receptors
comprised of three major classes, a1-, a2- and b-adrenergic
receptors, which are coupled to distinct intracellular signalling
pathways [14]. We have previously shown that stimulation of a2-
adrenergic receptors inhibits and b3-adrenergic receptor stimula-
tion activates hippocampal precursor activity both in vitro and in
vivo [1,15]. Recent reports also suggest enhanced hippocampal
progenitor turnover in response to b2-adrenergic receptor
stimulation [16]. Although these studies suggest differing effects
of these specific adrenergic receptors on hippocampal neurogen-
esis, we do not yet have a clear understanding of the stage-specific
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effects of adrenergic receptor activity in the regulation of
hippocampal neurogenesis.
In the present study, we systematically investigated the effects of
three major subclasses of adrenergic receptors in regulating
specific stages of hippocampal neurogenesis. Using the neuro-
sphere assay and a Nestin-GFP transgenic reporter mouse line, in
which hippocampal precursor cells are labeled, we examined the
effects of selective adrenergic receptor agonists and antagonists on
hippocampal precursor cell activation, proliferation and differen-
tiation. The term activation of hippocampal precursors indicates
the acquired ability of latent, non-proliferating hippocampal
precursor cells to respond to mitogens in vitro and generate
neurospheres. Our findings indicate that stimulation of a2-
adrenergic receptors significantly reduces the activation and
proliferation of the quiescent precursor cells. In contrast and as
previously reported, we found stimulation of b-adrenergic
receptors activates these precursor cells and increases their
proliferation. Moreover, blockade of b-adrenergic receptors leads
to a significant decline in quiescent and active precursor cell
populations and hippocampal neurogenesis. More importantly, we
now show that while stimulation of a2- adrenergic receptors
directly inhibits the Nestin-GFP-positive precursor cell population,
treatment with b-adrenergic receptor agonist results in activation
of this population. Furthermore, our results indicate no major role
for the a1-adrenergic receptor in regulating adult hippocampal
neurogenesis. These findings reveal that norepinephrine acts
through the a2- and b-adrenergic receptors to exert a direct but




Adult (8–12-week-old) male C57BL/6J mice were used for all
the in vitro experiments conducted in this study. 8–12 week-old
transgenic Nestin-GFP mice [17] were used to address the stage-
specific effects of adrenergic receptor manipulations on adult
hippocampal precursor cells and to isolate and enrich for
hippocampal precursor cells by flow cytometry. The Nestin-GFP
mice were bred on a C57BL/6J background and express green
fluorescent protein (GFP) under the control of the Nestin
promoter, thereby allowing visualization of the endogenous
population of neural precursors. All mice were housed in groups
and maintained on a 12-hour light/dark cycle with ad libitum
access to food and water.
Ethics Statement
All animal treatments and experimental procedures were
carried out in accordance with the National Institutes of Health
Guide, the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes and the guidelines of the Indian
Committee for the Purpose of Care and Supervision of Experi-
mental Animals. The experimental procedures were approved by
the Tata Institute of Fundamental Research Institutional Animal
Ethics Committee and The University of Queensland Animal
Ethics Committee.
Drugs and treatment
Selective agonists or antagonists of different adrenergic recep-
tors were used to study receptor effects on adult hippocampal
neural precursors and neurogenesis. All drugs were purchased
from Sigma-Aldrich and the in vitro concentrations used and the in
vivo dose administered are summarized in Table 1. For in vivo
treatment, all drugs were administered intraperitoneally (i.p.) once
daily for 7 days. The choice of drug dose was based on previous
studies [18–23]. 5-bromo-2-deoxyuridine (BrdU; 100 mg/kg;
Sigma), a thymidine analogue that is incorporated into the DNA
during the S-phase of the cell cycle, was used to label proliferating
precursors in the dentate gyrus. The animals were administered
BrdU 2 h after the last drug injection and were sacrificed 24 h
later (n = 4–6 mice per group). Each treatment had its own vehicle
group with 10% DMSO used as a vehicle for yohimbine and
prazosin, and 0.9% saline used for all other drugs.
Adult hippocampal neurosphere culture
Adult male C57BL/6J mice were killed by cervical dislocation
and their brains were removed and placed in ice-cold Hank’s
essential medium. The hippocampi were isolated from the
overlying cortex and minced using a scalpel blade. Minced tissue
was digested in 0.1% papain (Invitrogen) for 16 min at 37uC,
during which time the mixture was triturated gently to obtain a
single cell suspension. An excess of NeuroCult NSC basal medium
(Stem Cell Technologies) was added to halt the digestion, and the
cell suspension was centrifuged at 100 rcf for 5 min. The resulting
pellet was resuspended in 1 ml of complete neurosphere medium,
i.e. NeuroCult NSC basal medium containing NeuroCult prolif-
eration supplements (StemCell Technologies), 2% bovine serum
albumin (Invitrogen) 2 mg/ml heparin (Sigma-Aldrich) and growth
factors including 20 ng/ml epidermal growth factor (EGF;
receptor grade, BD Biosciences) and 10 ng/ml basic fibroblast
growth factor (bFGF; recombinant bovine, Roche). The cells were
then plated in a 96-well plate and cultured in complete neuro-
sphere medium containing EGF and bFGF in either the presence
or absence of L-(2)-noradrenaline (+)-bitartrate salt monohydrate
(norepinephrine; 10 mM). The dose responses of selective adren-
ergic receptor agonists and anatgonists were tested at various
concentrations (detailed in Table 1). Average live cells obtained
from 2 hippocampi were 3.5460.086105 and half of these cells
were used for each of the treatment conditions and plated in 48
wells. The medium containing growth factors was not replaced
during the 14-day term of the culture. On day 14, a total count of
the primary neurospheres was conducted for each of the
treatments and neurospheres were categorized based on size.
Values were expressed as a percentage relative to the control.
Neurosphere differentiation and immunocytochemistry
Control and treated neurospheres were collected on day 14 and
plated onto poly-D-lysine-coated BioCoat 8-well culture slides (BD
Biosciences) in serum-free basal medium (without mitogens). The
neurospheres were allowed to flatten and adhere for an additional
4 to 5 days in a humidified, 5% CO2 incubator. They were then
fixed with ice-cold 4% paraformaldehyde in 0.1 M phosphate-
buffered saline (PBS) for 30 min at 4uC and immunocytochemistry
was performed as described previously (Jhaveri et al., 2010), using
antibodies to the neuronal marker bIII tubulin (1:2000; Promega),
and the astrocytic marker glial fibrillary acidic protein (GFAP;
1:500; Dako Cytomation). 49,69-diamidino-2-phenylindole (DAPI;
1:5000; Sigma-Aldrich) was used as a nuclear stain. Slides were
mounted using fluoromount (Dako Cytomation) and viewed on a
Zeiss-Axio Imager microscope. Images were captured using a
digital camera linked to a computer using Zeiss software.
Fluorescence-activated cell sorting
Hippocampi from 3–4 Nestin-GFP mice (7–9 week old) were
isolated and a live-cell suspension prepared, as described earlier.
The dead cells were labeled with propidium iodide (1 mg/ml).
GFP-positive and -negative cells were sorted by flow cytometry
using FACS Aria (Becton Dickinson, Australia). The GFP-positive
Adrenoceptor Regulation of Adult Neurogenesis
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population was defined relative to the basal fluorescence levels
obtained from wild-type controls. The GFP-positive cells were
collected in neurosphere medium and plated into 96-well tissue
culture plates in four different conditions: EGF+bFGF only
(control), guanabenz (10 mM), isoproterenol (1 mM) or norepi-
nephrine (10 mM). The number of neurospheres obtained in each
of the conditions was quantified on day 14 and plotted as a
percentage of the control.
Immunohistochemistry
Animals were sacrificed by transcardial perfusion with ice-cold
4% paraformaldehyde (PFA), after which their brains were
removed and post-fixed in PFA. Serial coronal sections (50 mm
thick) through the rostro-caudal axis of the hippocampus were
generated using a vibratome (Leica). For BrdU immunohisto-
chemistry, every sixth section was selected and processed for
quantification (eight sections per animal). Briefly, BrdU immuno-
histochemistry involved DNA denaturation and acid hydrolysis,
followed by incubation with mouse anti-BrdU antibody (1:250;
Roche) overnight at 4uC. Sections were then incubated with
secondary antibody (biotinylated anti-mouse IgG, 1:500; Vector
Laboratories) for 3 h before amplification with an avidin-biotin
complex (Vector Laboratories) and visualization with diamino-
benzidine (Sigma). Sections were mounted using DPX (Qualigen,
India).
The number of immature neurons in the subgranular zone
(SGZ) was evaluated by performing doublecortin (DCX) immu-
nohistochemistry on four equivalent sections per animal for
control and treated groups. The sections were incubated overnight
with anti-DCX antibodies (goat anti-DCX, 1:250, Santa Cruz
Biotechnology or rabbit anti-DCX, 1:500, Abcam) before being
incubated with secondary antibodies, as described above.
The effect of adrenergic receptor perturbations on the Nestin-
positive pool of adult hippocampal precursors was quantified using
four sections per animal. Sections were incubated overnight with
rabbit anti-GFP (1:1000; Molecular Probes) followed by incuba-
tion in the secondary antibody (Alexa 488-conjugated donkey anti-
rabbit, 1:250; Molecular Probes) for 3 h. Double immunohisto-
chemistry for GFP and GFAP was carried out to label the
quiescent neural precursor population. The sections were incu-
bated overnight at room temperature in a cocktail of the primary
antibodies, rabbit anti-GFP (1:500; Invitrogen) and mouse anti-
GFAP (1:1000; Sigma). Sections were washed using 0.1 M PBS
and incubated for 3 h at room temperature with the secondary
antibody, a mixture of donkey anti-rabbit Alexa-488 and donkey
anti-mouse Alexa-547 (1:250; Molecular Probes). Sections were
mounted using Vectashield (Vector) and imaged using confocal
microscopy.
Cell counting analysis
The slides containing the sections were coded and quantifica-
tion performed by an experimenter blind to the code. BrdU-
positive cells were counted within the SGZ [15] on a Zeiss
Axioskop-2 Plus microscope. The number of BrdU-positive cells
per section was determined by assessing every sixth section across
the rostro-caudal extent of the hippocampus (10 sections/animal).
The number of DCX- and GFP-positive cells in the dentate gyrus
was quantified (four sections per animal) using a Zeiss Axioscope
and Nikon Eclipse 90i fluorescence microscope, respectively. The
cell counts are plotted as a percentage of the control (vehicle-
treated) for each adrenergic receptor agonist and antagonist. The
numbers of cells/section for all treatment conditions are shown in
Table S1.
The number of Nestin-GFP/GFAP double-positive cells was
quantified by determining the percentage of GFP-positive cells
that colocalized with GFAP using confocal microscopy. At least 50
GFP-positive cells from each animal (four sections per animal)
were analyzed using z-plane confocal sectioning with 1 mm steps
on a Zeiss LSM5 Exciter microscope.
Statistical analysis
All data are expressed as mean 6 standard error of the mean
(SEM). Results were subjected to statistical analysis using the
statistical software Prism (GraphPad) and analyzed using a
Student’s unpaired t-test for experiments with two groups or
one-way ANOVA for experiments with three groups or more
followed by the Bonferroni post hoc test. Significance was
determined at p,0.05.
Results
a1-adrenergic receptors do not regulate hippocampal
precursor activity or new neuron production in the adult
hippocampus
a1-adrenergic receptors are Gq-coupled receptors that are
widely expressed in the hippocampus [24,25] and have been
reported to stimulate proliferation in the subventricular zone and
also in the SGZ [26]. To determine whether a1-adrenergic
receptors play a role in regulating adult hippocampal neurogen-
esis, we first evaluated their effect on hippocampal precursor
activity in vitro using the selective a1-adrenergic receptor agonist,
cirazoline or the antagonist, prazosin. The neurosphere assay was
performed on a single-cell suspension of adult hippocampal cells
containing precursor that were treated with 100 nM, 1 mM, or
10 mM cirazoline or prazosin in the presence of EGF and bFGF.
Treatment with 10 mM norepinephrine was used as a positive
control based on our previous findings that showed norepineph-
rine-mediated activation of a quiescent population of adult
Table 1. Dose and concentrations of sub-class-selective adrenergic receptor agonists and antagonists used in this study.
Receptors Drugs In vivo (mg/kg/day) In vitro (mM)
AGONISTS a1-ARs Cirazoline 0.5 0.1, 1 and 10
a2-ARs Guanabenz 2 0.1, 1 and 10
b-ARs Isoproterenol 2 0.1, 1 and 10
ANTAGONISTS a1-ARs Prazosin 1 0.01, 0.1 and 1
a2-ARs Yohimbine 2 0.1, 1 and 10
b-ARs Propranolol 1 0.1, 1 and 10
doi:10.1371/journal.pone.0098736.t001
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hippocampal precursor cells [1]. In contrast to norepinephrine
treatment, which resulted in a ,2-fold increase in the number of
neurospheres, treatment with cirazoline or prazosin did not
change the total number of neurospheres obtained compared to
the control (Fig. 1A). Moreover, whereas 10 mM norepinephrine
resulted in a significant increase in the proportion of large
neurospheres (.200 mm in diameter), reflective of activation of a
true stem cell population, neither the agonist nor the antagonist
had any effect on neurosphere size compared to control (Fig. 1B).
Together, these data suggest that a1-adrenergic receptors do not
directly affect activation or proliferation of adult hippocampal
precursor cells.
To address whether a1-adrenergic receptors influence precursor
cell differentiation, we then examined neuronal production in the
neurospheres. Neurospheres generated in the presence of either
cirazoline or prazosin were differentiated by growth factor
removal and stained for the astrocytic marker GFAP and the
immature neuronal marker bIII tubulin (Fig. 1C, D, E). All
neurospheres contained GFAP-expressing astrocytes, however,
only ,40% of neurospheres contained bIII tubulin-positive
neurons in the control group. As previously reported, treatment
with norepinephrine resulted in a significantly higher proportion
of neurospheres that expressed bIII tubulin-positive neurons
(Fig. 1C, p,0.05). The percentage of neurospheres containing
bIII tubulin-positive neurons in the cirazoline- and prazosin-
treated groups was similar to that of the control group (Fig 1C).
To explore whether a1-adrenergic receptors influence adult
hippocampal neurogenesis in vivo, we assessed proliferation,
precursor cell number and number of DCX-immunopositive
immature neurons. Mice expressing GFP under the Nestin
promoter were used to evaluate the effects of a1-adrenergic
receptor manipulation on precursor cells (Fig. 1G). Cirazoline or
prazosin was administered once daily for a period of 7 days and
proliferation was assessed by BrdU immunohistochemistry
(Fig. 1F). Upon quantification, we found no change in the number
of BrdU-positive cells in the SGZ of cirazoline- and prazosin-
treated mice as compared to the vehicle-treated controls (Fig. 1I).
Similarly, no change in the number of Nestin-GFP cells was
observed between the control and the treatment groups (Fig. 1J),
suggesting that stimulating or blocking a1-adrenergic receptors
does not affect the total Nestin-positive precursor cell pool in vivo.
Moreover, the percentage of Nestin-GFP-positive cells that were
also immunopositive for GFAP (data not shown) as well as the
number of newborn DCX-immunopositive neurons (Fig. 1H, K)
were unchanged by a1-adrenergic receptor stimulation or
blockade. Taken together these findings indicate that a1-adren-
ergic receptors do not appear to influence the activation,
proliferation or differentiation of hippocampal precursor cells
and therefore, in a 7-day treatment paradigm, do not alter adult
hippocampal neurogenesis.
Stimulation of a2-adrenergic receptors inhibits
hippocampal precursor activity and decreases
hippocampal neurogenesis
Next, we examined the role of a2-adrenergic receptors in
regulating precursor cell activity and hippocampal neurogenesis
using a selective a2-adrenergic receptor agonist, guanabenz, and
an antagonist, yohimbine. Firstly, the direct effect of guanabenz
and yohimbine on adult hippocampal precursor cell population
was characterized in vitro. Treatment with 0.1 mM and 1 mM of
guanabenz had no effect, whereas 10 mM guanabenz resulted in a
significant reduction in the number of neurospheres (Fig. 2A)
compared to the control. This was consistent with our previous
study where we had observed a similar guanabenz-evoked decline
in hippocampal precursor activity in neurospheres derived from
postnatal day 7 rats [15]. In addition, the neurospheres generated
at this concentration were all less than 100 mm in diameter
(Fig. 2B), suggestive of reduced precursor cell proliferation.
Treatment of hippocampal precursor cells with the antagonist
yohimbine at 100 nM, 1 mM or 10 mM did not affect the number
nor the size of the neurospheres. The addition of 10 mM
norepinephrine resulted in the expected ,2-fold increase in the
number of neurospheres in this assay. The percentage of
neurospheres expressing both astrocytic and neuronal markers
was similar in the control, 10 mM guanabenz and 10 mM
yohimbine groups, suggesting that a2-adrenergic receptors do
not directly regulate differentiation of hippocampal precursor cells
(Fig. 2C).
To address the effects of a2-adrenergic receptors on the
hippocampal precursor cell pool and immature neuron numbers
in the hippocampal neurogenic niche in vivo, guanabenz,
yohimbine or vehicle was administered systemically once daily
for 7 days to Nestin-GFP mice. As reported previously [15], mice
treated with guanabenz had a significantly lower percentage of
BrdU-positive cells (42.3614.4%, p,0.05) as compared to the
vehicle-treated controls, whereas no change in the percentage of
proliferating cells was observed following yohimbine treatment
(84.466.3%, p.0.05; Fig. 2D, E). Intriguingly, guanabenz
treatment did not alter the total number of Nestin-GFP positive
cells (Fig. 2G). To further probe the population of precursor cells
affected by guanabenz, we performed dual labelling for Nestin-
GFP and GFAP, which has been shown to label the quiescent
precursor cells, and found a significant decline in the number of
double positive cells (Fig. 2H). Concomitantly, the percentage of
DCX-positive immature neurons was also significantly decreased
by this treatment (p,0.01, Fig. 2D, F) compared to the vehicle-
treated control group. In contrast, yohimbine administration did
not alter the total number of Nestin-GFP-positive precursors, the
percentage of GFP/GFAP-positive cells (Fig. 2G, I) or DCX-
positive immature neuron numbers (Fig. 2D, F) as compared to the
control group.
Collectively, these findings indicate that a2-adrenergic receptors
exert an inhibitory effect on hippocampal quiescent precursor cell
activity that results in a decline in new neuron production in the
adult hippocampus.
Stimulation of b-adrenergic receptors activates
hippocampal precursor cells and increases their
proliferation
Finally, we examined the effects of stimulating or blocking b-
adrenergic receptors using the selective b-adrenergic receptor
agonist isoproterenol or the antagonist propranolol, respectively.
In the neurosphere assay, treatment with 1 mM and 10 mM
isoproterenol resulted in a significant, and up to ,2-fold, increase
in neurosphere number. This was consistent with our previous
study, where we had found a similar increase in the number of
neurospheres in presence of a selective b3-adrenergic receptor
agonist BRL37344 [1]. Moreover, we found that treatment with
propranolol at 0.1 mM and 10 mM led to a significant decrease in
the number of neurospheres (Fig. 3A). As reported previously with
norepinephrine [1], a significant increase in the size of the
neurospheres was also observed in response to 1 mM isoproterenol,
particularly in the number of neurospheres measuring .200 mm
in diameter (Fig. 3B). While propranolol treatment did not affect
the size of the neurospheres (Fig. 3B), it significantly reduced the
proportion of neurospheres containing neurons (Fig. 3C).
In line with our previous findings [1], treatment of mice with
isoproterenol resulted in a significant increase in the number of
Adrenoceptor Regulation of Adult Neurogenesis
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Figure 1. Stimulation or blockade of a1-adrenergic receptors does no affect hippocampal precursor activity or neurogenesis. (A)
Treatment of adult hippocampal cells with norepinephrine (NE) leads to 2-fold increase in neurosphere numbers, however, treatment with cirazoline
or prazosin does not affect neurosphere formation at any dose (n = 4 experiments). (B) Neurospheres obtained in presence of norepinephrine were
Adrenoceptor Regulation of Adult Neurogenesis
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BrdU-positive proliferating precursor cells compared to control,
whereas propranolol treatment led to a significant decline (p,0.05;
Fig. 3D, E, F). Interestingly, treatment with isoproterenol evoked a
trend toward an increase in the total number of Nestin-GFP-
positive cells (p=0.06; Fig. 3G), however, no change in the Nestin-
GFP-positive cell number was observed following propranolol
treatment. Furthermore, a significant increase in the proportion of
Nestin-GFP/GFAP double-labeled cells was obtained following
isoproterenol treatment as compared to the vehicle-treated control
(p,0.01; Fig. 3H), once again reflecting an increase in the
quiescent precursor cell pool and reconfirming our previous results
[1]. In contrast, propranolol treatment decreased the percentage
significantly larger than that obtained in control medium containing EGF and bFGF. Again, cirazoline- or prazosin-treated neurospheres were
comparable to control (n = 4 experiments). (C) Relative percentage of the primary neurospheres expressing markers of astrocytes and neurons in
control, norepinephrine, cirazoline and prazosin-treated cultures (n = 5 experiments). While all neurospheres examined contained GFAP-positive
astrocytes, a significantly larger proportion of neurospheres expressed the neuronal marker, bIII tubulin, in the norepinephrine-treated versus the
control, cirazoline or prazosin group. The total number of neurospheres examined for each treatment group is indicated on the graph. An example of
control (D) and NE-derived (E) neurospheres showing immunofluorescence for GFAP (green) and bIII tubulin (red). Nuclei were stained with DAPI
(blue). Scale bars represent 100 mm. Note the presence of bIII tubulin-positive neurons in the norepinephrine-derived large neurosphere. Percentage
of BrdU-labeled cells in the SGZ was not altered following treatment with either cirazoline or prazosin once daily for 7 days (n = 5-6 mice per group, F,
I). Also, cirazoline or prazosin did not change the pool of Nestin-GFP-positive cells compared to the vehicle-treated control (G, J). Similarly, the
number of DCX-positive immature neurons remained unaltered following stimulation or blockade of a1-adrenergic receptors (H, K). (mean6SEM,
*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0098736.g001
Figure 2. Stimulation of a2-adrenergic receptors inhibits hippocampal precursor activity and decreases neurogenesis. (A) Treatment
of hippocampal precursor cells with a2-adrenergic receptor agonist at 10 uM significantly decreased neurosphere formation compared to the
control. Blockade of a2-adrenergic receptors with yohimbine had no effect of neurosphere activity (n = 5 experiments). (B) Treatment with either
guanabenz or yohimbine did not affect the size of hippocampal neurospheres. (C) Percentage of neurospheres displaying markers of neurons and
astrocytes were similar between control, guanabenz or yohimbine treatment. As expected, a significantly larger proportion of norepinephrine-treated
neurospheres contained neurons. The total number of neurospheres examined for each treatment group is indicated on the graph. (D)
Representative photomicrographs of BrdU- and DCX-labeled cells from control and guanabenz treated mice. (E) Quantitative analysis revealed a
significant reduction in BrdU-positive cells in SGZ of guanabenz but not yohimbine treated mice (n = 4-6 mice per group). Moreover, while neither
guanabenz nor yohimbine treatment showed any changes in the Nestin-GFP-positive population (G), guanabenz (H) but not yohimbine (I)
significantly reduced the percentage of Nestin-GFP/GFAP double-positive cells. Note the co-localization of GFP with GFAP in (H). The number of DCX-
positive cells was also significantly reduced in guanabenz-treated mice (F). (mean6SEM, *p,0.05, **p,0.01, ***p,0.01).
doi:10.1371/journal.pone.0098736.g002
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of Nestin-GFP/GFAP double-positive cells (p,0.001; Fig. 3I). A
significant reduction in the number of DCX-positive immature
neurons was also observed following propranolol treatment but the
DCX-positive neuronal population was unaltered in the isopro-
terenol-treated mice compared to the control (Fig. 3E, J).
These results extend our previous findings and suggest that b-
adrenergic receptors directly regulate both basal and stimulation-
dependent activation of precursor cells. Furthermore, they also
regulate the pool of DCX-positive new neurons in the adult
hippocampus.
Figure 3. Stimulation of b-adrenergic receptors enhances hippocampal precursor activity whereas blockade inhibits precursor
activity and decreases neurogenesis. (A) Treatment of primary hippocampal cells with b-adrenergic receptor agonist isoproterenol at 1 and
10 mM significantly increased where as with antagonist propranolol (0.1 and 10 mM) decreased neurosphere formation (n = 4 experiments). (B)
Neurospheres obtained in the presence of isoproterenol were similar to norepinephrine-derived neurosphere, particularly the emergence of a small
proportion of very large neurospheres measuring .200 mm in diameter. (C) A significantly large proportion of isoproterenol-treated neurospheres
contained both neurons and astrocytes similar to that observed in norepinephrine-derived neurospheres. Proportion of neurospheres expressing
neuronal marker bIII tubulin was significantly reduced in propranolol-treated neurospheres compared to control. (D, E) Representative
photomicrographs of BrdU- and DCX-labeled cells from control, isoproterenol and propranolol-treated mice. (F) In vivo administration of
isoproterenol increased whereas propranolol decreased the number of BrdU-positive cells in the SGZ (n = 4–5 mice per group). (G) While a trend
towards an increase in Nestin-GFP-positive cells was obtained following isoproterenol treatment, propranolol treatment did not alter GFP-positive cell
numbers in SGZ. (H) The percentage of Nestin-GFP/GFAP double-positive cells was significantly enhanced by isoproterenol treatment where as
propranolol treatment (I) led to a significant reduction in double-positive cells compared to the vehicle-treated control group. (J) Propranolol
treatment resulted in a significant reduction in DCX-positive immature neuron pool. (mean6SEM, *p,0.05, **p,0.01, ***p,0.01).
doi:10.1371/journal.pone.0098736.g003
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Stimulation of a2- adrenergic receptors directly inhibits,
whereas b-adrenergic receptor stimulation activates, the
adult hippocampal precursor cell population
The above results suggest that a2- and b-adrenergic receptors
regulate the same hippocampal precursor cell pool in opposite
fashions. To experimentally investigate this, we used flow
cytometry to purify Nestin-GFP-positive precursor cells from the
adult hippocampus (Fig. 4A). Nestin-GFP-positive cells (at a
density of less than 15 cells per well) were plated in control
medium or in media containing either guanabenz or isoproterenol.
Treatment with medium containing norepinephrine was used as a
positive control. The number of neurospheres obtained in
guanabenz-treated wells was significantly reduced compared to
the neurosphere number observed in control wells (p,0.05; n= 3;
Fig. 4B). In contrast, isoproterenol treatment led to a significant
(,3-fold; p,0.05) increase in the number of neurospheres as
compared to control conditions. This increase with isoproterenol
treatment was comparable to the enhanced neurosphere number
observed in the presence of norepinephrine. These results provide
strong evidence that a2- and b-adrenergic receptors directly
regulate the proliferative activity of the Nestin-positive precursor
cell population in an opposing fashion.
Discussion
Our in vitro neurosphere assay results, as well as the in vivo
findings from administration of adrenergic receptor-selective
agonists and antagonists, demonstrate that a2- and b-adrenergic
receptors exert direct and opposing effects on the regulation of
quiescent neural precursor cell activity, whereas a1-adrenergic
receptors do not appear to have a significant role in the regulation
of adult hippocampal neurogenesis (see Table 2).
The demonstration that guanabenz significantly decreased the
number of neurospheres, as well as the number of BrdU-positive
cells in the SGZ, suggests that a2-adrenergic receptors expressed
by hippocampal precursors play an inhibitory role in regulating
the cell cycle. Interestingly, we did not observe any effect on
precursor cell turnover following a2-adrenergic receptor blockade.
These results suggest that a2-adrenergic receptor exert a
stimulation-induced, but not a basal tonic, inhibitory effect on
adult hippocampal precursor cell turnover. On the other hand, b-
adrenergic receptors play an important role in regulating the
proliferation of precursor cells under basal condition. Importantly,
a direct effect on precursor cell activation and proliferation
observed following stimulation a2- and b-adrenergic receptors on
purified Nestin-GFP+ precursor cells is in agreement with our
previous data showing expression of these receptor subtypes on
freshly isolated precursors and in neurospheres [1,15]. This is
further supported by our previous finding that a decrease in
proliferation persists following a2-adrenergic receptor stimulation
in dopamine-b-hydroxylase knock-out mice, suggesting that the
effects are mediated by mechanisms involving post-synaptic
heteroceptors rather than pre-synaptic autoreceptors [15]. While
we have not directly examined whether a2- or b-adrenergic
receptors regulate precursor cell survival, no change in the number
of Nestin-GFP-positive cells following guanabenz or propranolol
treatment (Table S1) suggest that a decrease in precursor cell
proliferation rather than their death leads to an overall reduction
in BrdU and neurosphere numbers.
A major novel finding of our study is that the opposing effects of
a2- and b- adrenergic receptors on cell turnover are likely to
involve the same class of hippocampal precursors, those expressing
Nestin. Nestin-GFP/GFAP-expressing cells in the SGZ have been
proposed to contain quiescent precursor cell population (reviewed
in [5]). The finding that stimulation of a2-adrenergic receptors
reduced the percentage of Nestin-GFP/GFAP double-positive
cells and directly inhibited the ability of Nestin-positive precursor
cells to respond to mitogens in the neurosphere assay, whereas
stimulation of b-adrenergic receptors increased both the percent-
age of Nestin-GFP/GFAP double-positive cells in vivo and
significantly increased the number of neurospheres in vitro, strongly
suggests that these noradrenergic receptors maintain the prolifer-
ative balance between inhibition and stimulation of these Nestin-
positive hippocampal precursor cells. Moreover, as neurosphere
number is considered to be a read-out of the ‘active’ precursor
population capable of proliferation in the presence of growth
factors, we speculate that the changes observed in the percentage
of Nestin-GFP/GFAP double-positive cells within the neurogenic
niche may in fact reflect the activation status of quiescent
precursor populations. Further support for this idea comes from
Figure 4. Stimulation of a2-adrenergic and b-adrenergic receptors exerts opposing effects on proliferative activity of Nestin-
positive hippocampal precursor cells. (A) Nestin-positive cells from the adult hippocampus were sorted using flow cytometry based on their
GFP expression. (B) Treatment with the a2-adrenergic receptor agonist guanabenz directly and significantly inhibited Nestin-GFP-positive
hippocampal precursor cell proliferation as measured by a significant decline in neurosphere number. In contrast, treatment with the b-adrenergic
receptor agonist isoproterenol significantly increased Nestin-GFP-positive hippocampal precursor cell proliferation with an enhanced number of
neurospheres noted following isoproterenol treatment. The increased neurosphere numbers induced by isoproterenol were comparable to the
induction observed following norepinephrine treatment. (mean6SEM, *p,0.05, n = 3 experiments).
doi:10.1371/journal.pone.0098736.g004
Adrenoceptor Regulation of Adult Neurogenesis
PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e98736
our evidence that treatment with the b˜adrenergic receptor
antagonist propranolol led to a significant decrease in neurosphere
numbers, which was paralleled with a significant decline in the
percentage of Nestin-GFP/GFAP double-positive precursors
within the SGZ. Our previous studies suggest that the norepi-
nephrine-responsive population is likely to be distinct from the
population of precursors that responds to neuronal activity in the
adult hippocampal neurogenic niche [2,5]. Although our data
from flow cytometry-based experiments show that the opposing
effects of a2- and b-adrenergic receptors are indeed mediated on
the same class of Nestin-GFP-expressing hippocampal precursors,
further molecular evidence of possible subclasses present within
the Nestin-GFP/GFAP double-positive precursor pool cannot yet
be ruled out. However, it does indicate that stimulation of b-
adrenergic receptor with isoproterenol directly activates an
otherwise quiescent Nestin-GFP-positive precursor cells that now
become responsive to mitogens (EGF+bFGF).
Nonetheless, an important question that arises from this study is
the nature of a2- and b-adrenergic receptor balance within the
quiescent neural precursor population following norepinephrine
release in the hippocampus, which ultimately regulates precursor
cell proliferation and neurogenesis.
A possible answer lies in the effector systems downstream of a2-
and b-adrenergic receptors. Whereas a2-adrenergic receptors are
coupled to inhibitory G (Gi) proteins, resulting in inhibition of
adenylate cyclase, b-adrenergic receptors activate adenylate
cyclase through stimulatory G (Gs) proteins, thereby increasing
the levels of cAMP [14,27,28]. Previous studies have reported that
activation of the cAMP and cAMP response element-binding
protein (CREB) pathway as a positive regulator of hippocampal
neurogenesis and have suggested its role in mediating the
neurogenic effects of neurotransmitters and antidepressants [29–
34]. Specifically, the study by Nakagawa and colleagues [34]
suggested an enhancement in CREB phosphorylation as a possible
mechanism underlying precursor cell proliferation. Therefore, it is
possible that Gs versus Gi protein coupling of these adrenergic
receptors leads to changes in the levels of cAMP and phospho-
CREB, which may dictate the final outcome of stimulation versus
inhibition of neural precursor cell proliferation. Furthermore, the
significant reduction in the DCX-positive immature neuron
population observed following stimulation of a2- or inhibition of
b-adrenergic receptors could be attributed to downregulation of
the cAMP-CREB pathway, which has also previously been shown
to regulate hippocampal precursor cell differentiation [34]. Given
that the hippocampal precursor cells express both a2- and b-
adrenergic receptors, however, differences in stoichiometry of
these receptors, receptor coupling and oligomerization states as
well as possible heterocomplex formation could also serve to play
an important role in defining the nature of effects evoked by
norepinephrine on proliferation and differentiation of these
precursor cells.
A puzzling finding of this study was that isoproterenol treatment
resulted in enhanced proliferation both in vivo and in vitro, but only
increased neuronal production in vitro. This suggests that while
stimulation of b-adrenergic receptors leads to precursor cell
activation and proliferation in vivo, additional growth factors such
as those present in the neurosphere assay may be required to
increase neuronal differentiation, thus de-coupling activation/
proliferation of hippocampal precursors from their differentiation.
One cannot preclude the possibility that sustained isoproterenol
treatment may be required for differentiation or that the effects on
neuronal differentiation may only emerge in a delayed fashion
(more than two weeks) following the activation of quiescent
precursor cells. Future studies are required to address whether
specific adrenergic receptors can influence nestin-GFP-positive
precursors to adopt astrocytic and oligodendroglial fates.
To date, the role of a1-adrenergic receptors in regulating
various stages of neurogenesis in the hippocampus has not been
characterized in detail. Earlier studies have reported a positive role
for a1-adrenergic receptors in regulating neurogenesis in the
subventricular zone and subgranular zone using either transgenic
mice overexpressing a1-adrenergic receptors or selective agonists
[26,35]. These studies also demonstrated improvement in learning
and memory following long-term (up to 9 months) treatment with
the a1-adrenergic receptor agonist cirazoline, however, they did
not report any influence on hippocampal neurogenesis. Given that
we found no change in either precursor cell activation/prolifer-
ation nor in immature neuronal cell number in the dentate gyrus
following stimulation or inhibition of a1-adrenergic receptor
activity, it is possible that the beneficial effects of a1-adrenergic
receptors in improving cognition and mood involve mechanisms
independent of neurogenesis. Alternatively, a treatment regime of
more than 7 days may be required to exert positive effects on adult
hippocampal neurogenesis.
Finally, the differential effect on the proliferative activity of
hippocampal precursor cells exerted by a2- and b-adrenergic
receptors is particularly interesting in the context of the effects of
stress [36] and antidepressant treatments. Chronic stress models
Table 2. Summary of the stage-specific effects of sub-class selective adrenergic receptor agonists and antagonists on
hippocampal precursor activity and neurogenesis.
AR Receptor pharmacology Neurospheres Proliferation (BrdU+ cells) Nestin-GFP+ cells Nes-GFP/GFAP cells
Immature Neurons
(DCX+)
Cirazoline NC NC NC NC NC
Prazosin NC NC NC NC NC
Guanabenz r r NC r r
Yohimbine NC NC NC NC NC
Isoproterenol R R R * R NC




R *: p= 0.06.
doi:10.1371/journal.pone.0098736.t002
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that result in hippocampal neurogenic decline have been reported
to be associated with enhanced a2-adrenergic receptor expression
and binding within limbic brain regions [37,38]. In contrast,
chronic treatments with antidepressants that exert powerful pro-
neurogenic effects have been linked to a reduction in a2-
adrenergic receptor expression and signaling [39–41]. These
results suggest a model in which environmental influences such as
stress, aging and physical exercise may serve to influence the
extent of a2- versus b-adrenergic receptor expression or signaling
within the quiescent precursor cell populations, thereby differen-
tially modulating the effects of norepinephrine on precursor cell
activation and proliferation. This has clinical relevance given our
previous findings that combination therapy with drugs that block
a2-adrenergic receptor activity concomitant with elevation in the
levels of norepinephrine via transporter blockade (norepinephrine
re-uptake inhibitors) accelerates both neurogenic and antidepres-
sant-like effects [15]. Interestingly, a randomized double-blind
study in humans has reported a hastened antidepressant response
in clinically depressed subjects treated with a combination of
fluoxetine (selective serotonin re-uptake inhibitor) and yohimbine
[42].
Overall, our results demonstrate that stimulation of a2-
adrenergic receptors directly inhibit whereas that of b-adrenergic
receptors enhance Nestin-positive precursor cell activation and
proliferation, and implicate the balance from inhibitory to pro-
stimulatory effect as a possible novel mechanism to speed up
neurogenic effects of norepinephrine-elevating drugs.
Supporting Information
Table S1 Quantification showing average number of
BrdU-, DCX- and Nestin-GFP-labeled cells in mice
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